MIT Laser Biomedical Research Center

麻省理工学院激光生物医学研究中心(LBRC)为 生物医学社区。LBRC的核心设施位于G.R.哈里森光谱实验室，该实验室拥有 百年创新历史，为前沿技术提供了充满活力的环境 发展。在这种背景下，LBRC不断恢复活力，开发和传播光子解决方案 它解决了生物研究、药物开发和医学诊断中的复杂问题。这个 LBRC作为NIH的研究资源，为美国的生物和医学界服务了近30年， 在此期间，LBRC促成了一系列的研究，既有基础科学的，也有实用的 应用，服务于癌症生物学、心脏病学、传染病、血液学、干细胞的研究人员 生物学和神经生物学。我们成功地开发了技术研究和开发(TRD)计划 推动生物医学成像和诊断技术在荧光、干涉和振动方面的应用 分光镜。我们在建立卓有成效的合作伙伴关系方面有着良好的记录，我们与60多家 协作项目(CP)和服务项目(SP)在过去4年取得研究里程碑。 从数量上讲，在此期间，我们发表了100多篇同行评议的论文，其中许多具有很高的影响力 期刊，提交了8项专利披露，创办了3家公司，培训了15名中心工作人员，他们以良好的成绩离开了LBRC 职业生涯，在我们的合作者实验室培训了50多名员工，并通过 组织了50多个研讨会，在网上分发他们的内容。在下一个周期中，LBRC领导团队将 制定了一项创新和雄心勃勃的计划，通过从 三至七名高级调查人员，包括：苏永祥博士(主任)是非线性光谱学及 显微镜，Ramachandra Dasari博士(副主任)，拉曼光谱专家Mongi博士 Bawendi(联合董事)，量子点生物成像专家，Gabriela Schlau-Cohen博士， 单分子生物物理学和超快光谱学。伊桑·巴曼博士，表面增强拉曼研究专家 光谱学专家Conor Evans博士和专家Zahid Yaqoob博士 在干涉测量技术中。我们计划用四个TRD进入下一个周期：(1)荧光 光谱和显微技术，(2)干涉光谱和显微技术，(3) 拉曼光谱和显微技术，以及(4)用于生物医学的新一代纳米探针工具包 申请。虽然美国国立卫生研究院BTRCs涵盖了广泛的技术，但对开发的需求仍未得到满足 光学造影剂和纳米级探针。在纳米探测器上建立新的TRD4满足了这一需求 并实现与TRD1、2和3中开发的独特光谱检测方法的紧密集成。 与这些TRD合作，我们进一步建立了19个CP和19个SP，与我们的合作者合作 令人兴奋的生物医学研究的不同领域。

MIT Laser Biomedical Research Center (LBRC) provides state-of-the-art integrative photonic solutions for the biomedical community. The LBRC core facilities sit within the G.R. Harrison Spectroscopy Laboratory, which has a century-long history of innovation and provides a dynamic environment for cutting-edge technology development. Continually rejuvenated by this setting, the LBRC develops and disseminates photonic solutions that address complex problems in biological research, pharmaceutical development, and medical diagnosis. The LBRC has served the nation's biological and medical community as a NIH research resource for almost 30 years, and during this time, the LBRC has enabled a diverse range of research, both fundamental science and practical applications, serving investigators from cancer biology, cardiology, infectious disease, hematology, stem cell biology, and neurobiology. We successfully developed a technology research and development (TRD) program to advance biomedical imaging and diagnostic technologies using on fluorescent, interferometric, and vibronic spectroscopies. We have a proven track-record of building fruitful partnerships, with over sixty of our collaborative projects (CPs) and service projects (SPs) achieving research milestones in the past 4 years. Quantitatively, during this period, we have published over 100 peer reviewed papers with many in high impact journals, filed 8 patent disclosures, started three companies, trained 15 center staffed who left LBRC with good careers, trained over 50 staff in our collaborators' laboratories, and disseminated technologies through organizing over 50 seminars distributing their content online. In the next cycle, LBRC leadership team has formulated an innovative and ambitious plan to substantially enhance our expertise base by expanding from three to seven senior investigators including: Dr. Peter So (Director) is an expert in nonlinear spectroscopy & microscopy, Dr. Ramachandra Dasari (Associate Director), an expert in Raman spectroscopy, Dr. Moungi Bawendi (Associated Director), an expert in quantum dot bioimaging, Dr. Gabriela Schlau-Cohen, an expert in single molecule biophysics and ultrafast spectroscopy. Dr. Ishan Barman, an expert in surface enhanced Raman spectroscopy, Dr. Conor Evans, an expert in nonlinear Raman spectroscopy, and Dr. Zahid Yaqoob, an expert in interferometric technology. We plan to go forward into the next cycle with four TRDs: (1) fluorescence spectroscopy and microscopy techniques, (2) interferometric spectroscopy and microscopy techniques, (3) Raman spectroscopy and microscopy techniques, and (4) Next-generation nanoprobe toolkit for biomedical applications. While NIH BTRCs cover a broad range of technologies, there is unmet demand for development of optical contrast agents and nanoscale probes. Establishing the new TRD4 on nanoprobes addresses this need and enables tight integration with unique spectroscopic detection methods developed in TRD1, 2, & 3. In association with these TRDs, we have further established 19 CPs and 19 SPs working with our collaborators on diverse areas of exciting biomedical research.